Sutro Biopharma, Inc. (STRO) Stock Price & Analysis
Sutro Biopharma, Inc. (STRO) — MoonshotScore 17/100 (Weak band), calculated Oct 1, 2026. Price $15.97 (-0.87%), as of the Oct 1, 2026 trading session; market cap $155M.
Educational signal · not a buy or sell recommendation · How to read this
Sutro Biopharma, Inc. · STRO · NASDAQ
Sutro Biopharma, Inc. is a clinical-stage drug discovery, development, and manufacturing company focused on creating protein therapeutics for cancer and autoimmune disorders. Their XpressCF+ platform drives the development of antibody-drug conjugates (ADCs) and bispecific antibodies.
Price as of Oct 1, 2026
Key Statistics
MoonshotScore v2 · Sutro Biopharma (STRO)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Only growth holds up — quality and the balance sheet are near the sector floor; far more to fix here than to build on, and it’s expensive on top. Business Quality: Thin; Financial Safety: Strained; Valuation: Bubble; Growth Durability: Flat; Momentum: Slipping.
- quarterly revenue $10M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 2 of 8
- Altman Z -8.68 · Piotroski F 3
Holding back: weak fundamentals, balance-sheet strain, a rich price, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak |
The score was 17 in the stored Sep 30, 2026 snapshot and remains 17 in the current publication computed Oct 1, 2026 (0); the largest pillar moves were Momentum +3 and Business Quality -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $15.97 |
| Change on the day | -0.87% |
| 52-week range | $7.15 – $43.85 |
| Market capitalisation | $155M |
| Price / earnings (trailing) | -7.07 |
| Shares traded on the day | 196.4K |
Price & events
Council Score · weighted blend of 2 available disciplines
Council score for Sutro Biopharma (STRO): Split View
37/100 · DSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 2, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 2, 2026, except a card that shows its own read date.
Watch the STRO film — every key number, told as a short cinematic story
~2 min · open the film
What is Sutro Biopharma (STRO), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Sutro Biopharma, Inc. (STRO) is listed on NASDAQ. It employs 128 people and is led by Jane Chung. In Q2 FY2026 it reported revenue of $10M and net income of -$39M. The market values it at $155M.
What do the latest results show for Sutro Biopharma (STRO)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $10M. Against analyst estimates the company has EPS beat 2 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $10M | -$39M | -$2.33 (diluted) |
| Q1 FY2026 | $15M | -$38M | -$2.94 (diluted) |
| Q4 FY2025 | $12M | -$47M | -$5.45 (diluted) |
| Q3 FY2025 | $10M | -$57M | -$6.70 (diluted) |
What are the financial strengths and risks for Sutro Biopharma (STRO)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Altman Z -8.68 · Piotroski F 3. Trailing ratios: ROE 185.3% · ROA -92.9% · current ratio 3.32 · earnings yield -68.3% · free-cash-flow yield -94.2%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -8.68 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Sutro Biopharma (STRO)?
Short answer · as of
The stored analyst-target capture is expired, so a current target watchpoint is unavailable.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Sutro Biopharma compare with its peers?
Short answer
Sutro Biopharma's score ranks 2nd of 2 in the bounded comparison shown, against 1 same-model peer. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $143.79 Oct 1, 2026 | $355B | 75 5-pillar Oct 1, 2026 | |
| Sutro Biopharma (STRO) — this page | $15.97 | $155M | 17 |
| $31.23 Sep 9, 2026 | $8.73B | — Model unavailable | |
| $4.48 Date unavailable | $183M | — Model unavailable | |
| $9.98 Date unavailable | $119M | — Model unavailable | |
| $5.62 Date unavailable | $202M | — Model unavailable | |
| $2.68 Date unavailable | $213M | — Model unavailable | |
| $8.25 Date unavailable | $246M | — Model unavailable | |
| $16.81 Date unavailable | $89.2M | — Model unavailable | |
| $9.60 Date unavailable | $86.9M | — Model unavailable | |
| $7.81 Date unavailable | $553M | — Model unavailable | |
| $7.42 Date unavailable | $582M | — Model unavailable | |
| $10.56 Date unavailable | $624M | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Sep 29, 2026)
- $43.00 – $60.00
- Last captured analyst target (expired, captured Sep 29, 2026)
- $51.00
- Last captured median analyst target (expired, captured Sep 29, 2026)
- $50.00
Historical target record · Captured · Capture expired; not a current watchpoint.
Insider activity
Form 4 records via FMP · Available records within the last 180 days, newest dated Jun 5, 2026 (coverage not recorded)
- Transactions
- 10
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 0
- Other transactions
- 10
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Sutro Biopharma (STRO)?
Common Questions About STRO
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for STRO?
STRO carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is STRO a good stock to buy?
Stock Expert AI does not rate STRO buy, sell or hold. Sutro Biopharma, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the STRO stock price today?
The last price recorded on this page for Sutro Biopharma, Inc. (STRO) is $15.97, as of the Oct 1, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the STRO price target?
The last analyst consensus price target we captured for Sutro Biopharma, Inc. (STRO) was $51.00 (range $43.00 to $60.00, median $50.00), from FMP on Sep 29, 2026. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
What are the key factors to evaluate for STRO?
Sutro Biopharma, Inc. (STRO) holds a MoonshotScore in the low range. Collaboration agreements with Merck and Celgene validate the company's technology and provide financial resources for pipeline development. Not financial advice.
How frequently does STRO data refresh on this page?
STRO's price is the last quote we recorded, from the Oct 1, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven STRO's recent stock price performance?
Sutro Biopharma, Inc. (STRO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary XpressCF+ platform enables rapid and efficient development of protein therapeutics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider STRO overvalued or undervalued right now?
Sutro Biopharma, Inc. (STRO) is loss-making, so its trailing P/E is negative (-7.07x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of STRO?
Fractional-share availability for Sutro Biopharma, Inc. (STRO) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (21 figures)
The 21 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 13 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $15.97 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-01T20:44:55.726Z. | |
px.change | Change on the day | -0.87% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $155M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-01. FMP quote timestamp: 2026-10-01T20:00:00.000Z. Captured from FMP at 2026-10-01T20:44:54.895Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.14 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $10M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | -7.07 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 196.4K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q2 FY2026 | -$39M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt_range | Last captured analyst target range, low to high (expired, captured Sep 29, 2026) | $43.00 – $60.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Sep 29, 2026 · Coverage not supplied · Capture expired | |
earn.pt_consensus | Last captured analyst target (expired, captured Sep 29, 2026) | $51.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Sep 29, 2026 · Coverage not supplied · Capture expired | |
earn.pt_median | Last captured median analyst target (expired, captured Sep 29, 2026) | $50.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Sep 29, 2026 · Coverage not supplied · Capture expired | |
own.insiders | Insider transactions via FMP | 10 transactions · 0 purchases, 0 sales, 10 other transactions · 9 identified insiders · available records within the last 180 days, newest dated Jun 5, 2026 (coverage not recorded) | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 2 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-24 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -8.68 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-09-29 · Expired observation | |
px.range52 | 52-week range | $7.15 – $43.85 | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
id.employees | Employees | 128 | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
id.ceo | Chief executive | Jane Chung | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 185.3% · ROA -92.9% · current ratio 3.32 · earnings yield -68.3% · free-cash-flow yield -94.2% | — | UNRECORDED | Stored key metrics — Date unknown |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 17 of 100 · Weak · pillars 24 / 32 / 6 / 59 / 34 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 17 (stored snapshot Sep 30, 2026) → 17 (current publication computed Oct 1, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.